## Causal Inference Case Studies

#### Irene Y. Chen







## Housekeeping


- 1. IBM announcement from Willie
- 2. Midsemester feedback form
  - We read every comment
  - Already taking suggestions into account
- 3. Final project mentors
  - Received initial feedback
  - Email TAs with questions
- 4. HW5 out
  - Mystery poll??

## Agenda for today


- 1. Housekeeping
- 2. Review lecture material [15 mins]
- 3. Post surgical opioid abuse [15 mins]
- 4. Diabetes treatment management [15 mins]

**Goal:** learn practical causality analysis tools for homework, final projects, and beyond

## You inherit a tobacco company in the 1950's




smoking




lung cancer

## Does smoking cause cancer?




Observed association; cannot do randomized control trial

## Does cancer cause smoking?



Probably not: Smoking begins years before diagnosis.

## Does smoking cause cancer?




How can we estimate ATE = E[Y=1|T=1,X] - E[Y=0|T=0,X]?

### Three ML methods to control for confounders

- 1. Covariate adjustment
- 2. Matching
- 3. Propensity scoring

# Explicitly model the relationship between treatment, confounders, and outcome:



[Slide 4 of lecture 15]

## Covariate adjustment (reminder)

• Under ignorability, CATE(x) =  $\mathbb{E}_{x \sim p(x)} \Big[ \mathbb{E}[Y_1 | T = 1, x] - \mathbb{E}[Y_0 | T = 0, x] \Big]$ 

• Fit a model  $f(x,t) \approx \mathbb{E}[Y_t | T = t, x]$ , then:  $\widehat{CATE}(x_i) = f(x_i, 1) - f(x_i, 0)$ .

## Recap: Covariate adjustment

- "Plug in different values of treatment and see what happens"
- Assumes we have a very accurate and calibrated f(x,T)
- If data is nonlinear and we assume linearity, CATE and ATE estimates can be very misleading
- Recent research has investigated using different model classes for f, e.g. random forests and neural networks.
   We must then figure out how to modify the learning criteria

## Matching

 Find each unit's long-lost counterfactual identical twin, check up on his outcome



Obama, had he gone to law school



Obama, had he gone to business school

## 1-NN Matching

- Let  $d(\cdot, \cdot)$  be a metric between x's
- For each i, define  $j(i) = \underset{j \text{ s.t. } t_j \neq t_i}{\operatorname{argmin}} d(x_j, x_i)$ j(i) is the nearest counterfactual neighbor of i
- $t_i = 1$ , unit i is treated:

$$\widehat{CATE}(x_i) = y_i - y_{j(i)}$$


•  $t_i = 0$ , unit i is control:

$$\widehat{CATE}(x_i) = y_{j(i)} - y_i$$
[Slide 18 of lecture 15]

## Recap: Matching

- "Approximate my long lost twin and compare results"
- Useful for both CATE and ATE
- In practice, difficult because of finding right distance function and having enough twins
- Not used widely (yet!)

## What if the populations are different?



Income


## Propensity score reweighting

$$A\hat{T}E = \frac{1}{n} \sum_{i \text{ s.t. } t_i = 1} \frac{y_i}{\hat{p}(t_i = 1|x_i)} - \frac{1}{n} \sum_{i \text{ s.t. } t_i = 0} \frac{y_i}{\hat{p}(t_i = 0|x_i)}$$

## Recap: Propensity score reweighting

- "Give higher weight to lower represented samples"
- Can only calculate ATE
- Requires some overlap of the populations and good estimator p\_hat
- If denominator is too low, weights can explode quickly

### What about instrumental variables?




We can then estimate Wald estimator Cov(Y,B) / Cov(T,B)

## Agenda for today

- 1. Housekeeping
- 2. Review lecture material [15 mins]
- 3. Post surgical opioid abuse [15 mins]
- 4. Diabetes treatment management [15 mins]

#### **Drug overdose deaths in America**


\*Some deaths on this chart may overlap if they involve multiple drugs.



[Centers for Disease Control]

Opioid painkillers (natural and semisynthetic)

# Share of organ donors who died of drug overdoses





#### Research

# Postsurgical prescriptions for opioid naive patients and association with overdose and misuse: retrospective cohort study

BMJ 2018; 360 doi: https://doi.org/10.1136/bmj.j5790 (Published 17 January 2018)

Cite this as: BMJ 2018;360:j5790

Article

Related content

Metrics

Responses

Peer review

Gabriel A Brat, instructor in surgery <sup>1</sup> <sup>2</sup>, Denis Agniel, postdoctoral fellow <sup>1</sup>, Andrew Beam, research scientist <sup>1</sup>,

Brian Yorkgitis, assistant professor in surgery <sup>3</sup>, Mark Bicket, assistant professor in anesthesia <sup>4</sup>, Mark Homer, postdoctoral fellow <sup>1</sup>,

Kathe P Fox, director <sup>5</sup>, Daniel B Knecht, chief of staff <sup>5</sup>, Cheryl N McMahill-Walraven, director <sup>5</sup>,


Nathan Palmer, research scientist <sup>1</sup>, Isaac Kohane, department chair <sup>1</sup>

#### Author affiliations >

Correspondence to: G A Brat gbrat@bidmc.harvard.edu

Accepted 1 December 2017

## Do postsurgical opioids cause opioid abuse?



#### Aetna Insurance claims

#### Pros

- Complete patient record
- Hospital and pharmacy care
- Surgical claims from CPT, outcomes from ICD-9 codes

#### Cons

- Lacking granular information about hospital stays (e.g. lab values)
- CPT and ICD-9 codes can be incorrect or manipulated for billing purposes

#### Data source


#### Include

- Patients with "complete" medical and pharmacy insurance records
- Underwent first surgery
- Opioid naïve: little/no previous opioid use

#### Final cohort

- Large dataset (37 million)
- Longitudinal (2008-2016)
- After inclusion criteria, 1 million opioid naïve patients undergoing surgery

## Do postsurgical opioids cause opioid abuse?



## How do we define T, Y, and X?

#### What is treatment T?

- Refill
- Total dosage
- Duration of use

#### What is outcome Y?

- ICD-9 code for opioid dependence, abuse, and overdose
- Only include diagnosis codes related to prescription opioids

#### What are confounders X?

- Demographics (age, sex)
- US state of residence
- surgery type group
- surgery year
- presurgical diagnoses

## Statistical analysis

- Weighted linear regression for log transformed weekly rates of misuse
  - Each week weighted according to sample size
  - Create outcome of adjusted analysis of time until misuse event using Cox proportional hazards (survival analysis!)
  - Results report multiplicative percentage increases in rate
- Sensitivity analysis to rule out structural confounders
  - Interaction term between duration and year indicator
  - Interaction between duration and state of residence indicator
  - Build in an unobserved confounder with a Bernoulli random variable

## Recap: Postsurgical opioid use to misuse

- "Duration more than dosage use may cause opioid misuse"
- Use covariate adjustment to estimate multiplicative effects
- Interaction terms

## Agenda for today

- 1. Housekeeping
- 2. Review lecture material [15 mins]
- 3. Post surgical opioid abuse [15 mins]
- 4. Diabetes treatment management [15 mins]

#### Personalized Diabetes Management Using Electronic Medical Records

Dimitris Bertsimas , Nathan Kallus, Alexander M. Weinstein and Ying Daisy Zhuo

+ Author Affiliations

Corresponding author: Dimitris Bertsimas, dbertsim@mit.edu.

Diabetes Care 2017 Feb; 40(2): 210-217.

https://doi.org/10.2337/dc16-0826






#### Abstract

OBJECTIVE Current clinical guidelines for managing type 2 diabetes do not differentiate based on patient-specific factors. We present a data-driven algorithm for personalized diabetes management that improves health outcomes relative to the standard of care.

## Type 2 Diabetes Treatment Still a Mystery



Male

BMJ Open. 2015; 5(5): e007375.

Published online 2015 May 12. doi: 10.1136/bmjopen-2014-007375

Racial ethnic differences in type 2 diabetes treatment patterns and glycaemic control in the Boston Area Community Health Survey

Sunali D Goonesekera, May H Yang, Susan A Hall, Shona C Fang, Rebecca S Piccolo, and John B McKinlay

▶ Author information ▶ Article notes ▶ Copyright and License information Disclaimer

Diabetologia. Author manuscript; available in PMC 2014 Dec 1.

Published in final edited form as:

Diabetologia. 2013 Dec; 56(12): 10.1007/s00125-013-3078-7.

Published online 2013 Oct 5. doi: 10.1007/s00125-013-3078-7

PMCID: PMC3842214

NIHMSID: NIHMS529351

PMID: 24092493

PMCID: PMC4431069

PMID: 25967997

Age-related differences in glycaemic control in diabetes

Elizabeth Selvin 1 and Christina M. Parrinello 1

## What do we include in this analysis?

#### Inclusion criteria

- Patients in hospital EMR for >1 year
- Prescription for at least one blood glucose regulation agent
- At least three recorded laboratory results for HbA1C
- No recorded diagnosis of type 1 diabetes (from ICD-9 code 250.x1 or 250.x3)


#### Final cohort

- 10k patients, 48k patient visits
- Access to demographic information
- Analyze all associated EMR data

## What makes two patients similar or different?


#### **Features**

- Differentiate 13 lines of therapy
- Patient visit every 100 day and average HbA1C after visit (75-200 days after)
- Collect what standard of care was actually administered




[Slide 17 of lecture 15]

### Which treatment will lead to lower HbA1C?



### Model

- For each patient visit, find kNN regression to predict HbA1C under every possible treatment
- Algorithm prescribes regimen with best predicted outcome if predictive improvement exceeds threshold
- Evaluation compared actual treatment and outcome with recommended therapy and outcome
- Sensitivity analysis by drawing new training and testing splits



[Figure 1 of Bertsimas et al, 2017]

#### **Recommendation:** Switch from insulin monotherapy to metformin monotherapy Predicted HbA1c (%): 8.3 Outcomes for similar patients who were prescribed... insulin + non-metformin oral agent insulin **PATIENT ID** 12XXXXX **CURRENT** Mean 9.4 Mean 9.2 AGE (Years) 61.9 (SD 1.2) (SD 1.1) SEX F RACE/ETHNICITY Black **CURRENT HbA1c (%)** 10.1 metformin metformin + insulin **CURRENT REGIMEN** Insulin RECOMMEND Mean 8.3 Mean 9.7 (SD 1.5) (SD 1.8) Patient Treatment & HbA1c History Sulfonylurea -Insulin non-metformin oral agent no treatment Mean 9.6 Mean 9.5 5-(SD 1.6) 15-(SD 1.5) HbA1c

2001

15

15 0

HbA1c

[Figure 2 of Bertsimas et al, 2017]

2003

2004

2002

## Recap: Diabetes treatment management

- "kNN over patients can recommend diabetes treatments"
- Use matching to estimate different treatment effects
- Evaluate by comparing predicted and actual treatment and HbA1C values
- Sensitivity analysis through repeated sampling of training and test data

# Have a great weekend!